# A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

> **NCT02019277** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 50 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Nab-paclitaxel
- **DRUG:** Paclitaxel
- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT02019277
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-05
- **Primary completion:** 2016-11-04
- **Final completion:** 2016-11-04
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02019277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02019277, "A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02019277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*